By Elliot Gulliver-Needham In this weekly series, investment reporter Elliot Gulliver-Needham sits down with a fund manager for a Q&A. This week, we’re hearing from Ailsa Craig, co-portfolio manager of International Biotechnology Trust. How does your fund stand out from others in the same market?While many companies in the biotechnology sector are proven, cash-generating businesses, those at an earlier stage of drug development can see their success hinge on binary events like clinical trial results. At International Biotechnology Trust, we aim to mitigate this risk by lowering our exposure to…